About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.


Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. More >

News & Events

Oct 05, 2015 MannKind to Present at Aegis Capital Corp. 2015 Growth Conference More >
Sep 04, 2015 MannKind Announces Renewal of Shelf Registration and ATM Agreements More >
Aug 10, 2015 MannKind Corporation Reports 2015 Second Quarter Financial Results More >